ALA-3000

Small molecule

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1 (1)
Major Depressive Disorder

Competitive landscape

This mechanism is crowded: 11 other tracked programmes target it, 9 of them ahead of this one.

This drug's own stage for Major Depressive Disorder: Phase 1. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
ALA-3000: this drugPhase 1Small moleculeNMDA receptorPartial signalFeatured results are safety only in this race
Amantadine ER (Gocovri / ADS-5102)
Approved(overall)
Small moleculeNMDA receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Aripiprazole (Abilify)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptornot yet gradedNo reviewed efficacy summary in this indication
Brexpiprazole (Rexulti)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptorPartial signal
NCT01360645: Change From Baseline (End of Phase A [Week 8]) to Week 14 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score for the Efficacy Sample. (Baseline and Week 14): Brexpiprazole 2 mg/Day + ADT -8.27 Units on a scale (Standard Error 0.61) vs Double-blind Placebo + ADT -5.15 Units on a scale (Standard Error 0.6)
NCT01360632: Mean Change From the End of Phase A (Week 8 Visit) to Phase B (Week 14 Visit) in the Montgomery-Asberg Depression Rating Scale for the Efficacy Sample Set (Baseline and Week 14): Brexpiprazole (1mg) + ADT -7.65 Units on a scale (Standard Error 0.5) | Brexpiprazole (3mg) + ADT -7.98 Units on a scale (Standard Error 0.51) vs Placebo + ADT -6.45 Units on a scale (Standard Error 0.51)
Cariprazine (Vraylar)ApprovedSmall moleculeDopamine D3/D2 receptor (partial agonist)Partial signal
NCT03738215: Total Score Change From Baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale) (Baseline and Week 6): Cariprazine 1.5 mg/Day + ADT -14.1 score on a scale (Standard Error 0.7) | Cariprazine 3 mg/Day + ADT -13.1 score on a scale (Standard Error 0.7) vs Placebo + ADT -11.5 score on a scale (Standard Error 0.7)
Dextromethorphan / Bupropion (Auvelity)ApprovedSmall moleculesigma-1/NMDA, Dopamine/norepinephrine transporterPartial signal
NCT04019704: Change in MADRS Total Score From Baseline to Week 6 (6 weeks): AXS-05 15.91 score on a scale (Standard Error 0.921) vs Placebo 12.04 score on a scale (Standard Error 0.862)
NCT02741791: Primary endpoint, MADRS total score change from baseline to Week 6: -11.6 with AXS-05 vs -9.4 with bupropion (active comparator); difference not statistically significant, p=0.117 missed
Duloxetine (Cymbalta)ApprovedSmall moleculeSerotonin/norepinephrine transporter, Serotonin and norepinephrine transporters (SERT/NET)not yet gradedNo reviewed efficacy summary in this indication
Esketamine (Spravato)ApprovedSmall moleculeNMDA receptorPartial signal
NCT02418585: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 in the Double-blind Induction Phase- Mixed-Effects Model Using Repeated Measures (MMRM) Analysis (Baseline up to Day 28 of Double-blind Induction Phase): Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) -21.4 Units on a scale (Standard Deviation 12.32) vs Intranasal Placebo Plus Oral AD -17 Units on a scale (Standard Deviation 13.88)
NCT02417064: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 of Double- Blind Induction Phase- Mixed- Effects Model Using Repeated Measures (MMRM) Analysis (Baseline up to Day 28 of Double-blind Induction Phase): Intranasal Esketamine 56 mg Plus Oral Antidepressant -19 Units on a scale (Standard Deviation 13.86) | Intranasal Esketamine 84 mg Plus Oral AD -18.8 Units on a scale (Standard Deviation 14.12) vs Oral AD Plus Intranasal Placebo -14.8 Units on a scale (Standard Deviation 15.07) missed
Lumateperone (Caplyta)ApprovedSmall moleculeSerotonin 5-HT2A / dopamine D1-D2 receptorWeak signal
NCT05061706: Montgomery-Asberg Depression Rating Scale (Day 43): Lumateperone 42 mg -14.7 units on a scale (Standard Error 0.56) | Placebo -10.2 units on a scale (Standard Error 0.54)
NCT04985942: Montgomery-Åsberg Depression Rating Scale (Day 43): Lumateperone 42 mg -14.7 score on a scale (Standard Error 0.54) | Placebo -9.8 score on a scale (Standard Error 0.53)
Quetiapine (Seroquel XR)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Vortioxetine (Trintellix)ApprovedSmall moleculeSerotonin transporter + multiple 5-HT receptorsPartial signal
NCT00596817: Relapse Within First 24 Weeks of the Double-blind Period Based on a MADRS Total Score >=22 or an Unsatisfactory Treatment Effect (Lack of Efficacy) as Judged by the Investigator (Within first 24 weeks of the double-blind period): Vortioxetine: 5 or 10 mg 13.2 percentage of patients who relapsed vs Placebo 26 percentage of patients who relapsed
NCT02709655: Change From Baseline in Children Depression Rating Scale - Revised (CDRS-R) Total Score at Week 8 of Phase B (Baseline (Week 4 of Phase A), Week 8 of Phase B): Double-Blind: Vortioxetine 10 mg -19.2 units on a scale (Standard Error 1.37) | Double-Blind: Vortioxetine 20 mg -19.94 units on a scale (Standard Error 1.37) vs Double-Blind: Placebo -17.48 units on a scale (Standard Error 1.35) | Double-Blind: Fluoxetine 20 mg -20.78 units on a scale (Standard Error 1.6) missed
AmmoxetinePhase 3Small moleculeSerotonin/norepinephrine transporterPartial signal
NCT06827431: Primary endpoint, week-8 MADRS change: significantly better than placebo (P<0.0001) and numerically better than sertraline (2026-07-27).
Ansofaxine HydrochloridePhase 3Small moleculeSerotonin/norepinephrine/dopamine transporterReliable signal
NCT04853407: MADRS total score change from baseline at Week 8: ansofaxine 80 mg -20.0, ansofaxine 160 mg -19.9, placebo -14.6 (p<0.0001).
AzetukalnerPhase 3Small moleculeKv7 potassium channelnot yet gradedNo reviewed efficacy summary in this indication
BrenipatidePhase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
DeupsilocinPhase 3Small molecule5-HT2A receptorPartial signal
NCT05385783: Primary endpoint (3-week MADRS change vs placebo): -14.08 point difference after a single 12mg dose (p=0.0005, Cohen's d=2.151)
KH607Phase 3Small moleculeGABA-A receptorPartial signalNo reviewed efficacy summary in this indication
LB-102 (methylated Amisulpride)
Phase 3(overall)
Small moleculeDopamine D2/D3 receptor + 5-HT7 receptornot yet gradedNo reviewed efficacy summary in this indication
Lysergide Tartrate (LSD) (DT120)Phase 3Small molecule5-HT2A receptorReliable signal
NCT06941844: Emerge (NCT06941844), primary endpoint LS mean change in MADRS total score at Week 6: DT120 ODT 100 µg -13.3 vs placebo -5.2; LS mean difference -8.1 points; p<0.0001.
Milsaperidone (VHX-896)Phase 3Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
OsavampatorPhase 3Small moleculeAMPA receptor (positive allosteric modulator)Partial signal
NCT05203341: MADRS total score change at Day 28 vs placebo (company topline): one dose -4.3 (p = 0.0159); the other dose -3.0 (p = 0.0873, not significant). Day 56: -7.5 (p = 0.0016) and -3.6 (p = 0.1082).
Psilocybin (COMP360)Phase 3Small molecule5-HT2A receptorReliable signal
NCT05711940: COMP006 (NCT05711940), primary endpoint MADRS change at week 6: COMP360 25 mg vs 1 mg difference -3.8 points; p<0.001.
NCT05624268: Change in MADRS total score from baseline to Week 6 (COMP005 trial): COMP360 25 mg vs placebo, mean treatment difference -3.6 points (95% CI -5.7 to -1.5; p<0.001)
SeltorexantPhase 3Small moleculeOrexin-2 receptor (OX2R)Partial signal
NCT04533529: Double Blind (DB) Treatment Phase: Change From Baseline to Day 43 in Montgomery- Asberg Depression Rating Scale (MADRS) Total Score- Estimand 1 (Baseline (Day 1), Day 43): DB Treatment Phase: Seltorexant 20 mg -12.9 Units on a scale (Standard Deviation 9.63) vs Double Blind (DB) Treatment Phase: Placebo -10.5 Units on a scale (Standard Deviation 10.26)
NCT04513912: Response (>=50% MADRS improvement) at week 26: 57.4% seltorexant vs 53.4% quetiapine XR; did not reach statistical significance missed
Solriamfetol (Sunosi)Phase 3Small moleculeDopamine/norepinephrine transporterPartial signal
NCT06360419: In the overall patient population the study did not demonstrate a statistically significant change on the Montgomery-Asberg Depression Rating Scale (MADRS) total score compared to placebo, the study's primary endpoint. Patients with MDD with severe excessive daytime sleepiness (n=51) and without severe EDS (n=295) were randomized to solriamfetol 300 mg or placebo. missed
D-Cycloserine / Lurasidone (NRX-101)Phase 2/3Small moleculeNMDA receptor (glycine site) + dopamine/5-HT receptornot yet gradedNo reviewed efficacy summary in this indication
Mitizodone PhosphatePhase 2/3Small moleculeSerotonin transporter/5-HT receptorWeak signalNo reviewed efficacy summary in this indication
ACP-211Phase 2Small moleculeNMDA receptornot yet gradedNo reviewed efficacy summary in this indication
ALTO-100Phase 2Small moleculeFirst-in-class oral small molecule neural plasticity enhancerPartial signal
NCT05117632: MADRS reduction at Week 6: 15.5 points (biomarker-defined group) vs 10.6 points (biomarker-negative group); clinical response (>=50% MADRS reduction): 61% vs 33%
ALTO-203Phase 2Small moleculeHistamine H3 receptor (antagonist / inverse agonist)Partial signalNo reviewed efficacy summary in this indication
ALTO-300Phase 2Small moleculeMelatonergic (MT) receptors (agonist) + serotonin receptorWeak signalNo reviewed efficacy summary in this indication
Arketamine (PRT042)Phase 2Small moleculeNMDA receptornot yet gradedNo reviewed efficacy summary in this indication
AV-101Phase 2Small moleculeNMDA receptorPartial signal
NCT02484456: Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 0): AV 101 (4-chlorokynurenine) 20.22 score on a scale (Standard Error 0.68) vs Placebo 20.56 score on a scale (Standard Error 0.51) missed
BI 1569912Phase 2Small moleculeNMDA receptorPartial signal
NCT06558344: Change From Baseline in MADRS Total Score at Week 6 (MMRM included measurements at baseline, Day 8, Week 2, Week 4, and Week 6. Change from baseline values at Week 6 is reported.): 5 mg BI 1569912 -13.6 Units on a scale (95% CI -17.8 to -9.4) | 10 mg BI 1569912 -10.6 Units on a scale (95% CI -14.5 to -6.7) | 20 mg BI 1569912 -10 Units on a scale (95% CI -12.9 to -7.2) vs Placebo-matching BI 1569912 -10.3 Units on a scale (95% CI -13.1 to -7.5) missed
NCT06280235: Change From Baseline in MADRS Total Score at Week 6 (MMRM included measurements from baseline and Day 8, Week 4, Week 6 after first drug administration. MMRM estimates of change from baseline to Week 6 in MADRS total score is reported.): 5 mg BI 1569912 -7.8 units on a scale (95% CI -11 to -4.6) | 10 mg BI 1569912 -11.9 units on a scale (95% CI -15 to -8.7) | 20 mg BI 1569912 -12.3 units on a scale (95% CI -14.6 to -10) vs Placebo -12 units on a scale (95% CI -14.2 to -9.7) missed
BlixeprodilPhase 2Small moleculeNMDA receptorWeak signalFeatured results are safety only in this race
BPL-003 (mebufotenin Benzoate)Phase 2Small molecule5-HT2A receptorPartial signal
NCT05870540: MADRS change from baseline at Day 29: 12 mg BPL-003 -11.1 points vs -5.8 points for 0.3 mg comparator arm (p=0.0038); 8 mg BPL-003 -12.1 points vs 0.3 mg comparator (p=0.0025).
BretisilocinPhase 2Small molecule5-HT2A receptornot yet gradedNo reviewed efficacy summary in this indication
Cyclobenzaprine (Tonmya)Phase 2Small molecule5-HT2A, α1-adrenergic, H1-histaminergic, and M1-muscarinic acetylcholine receptors (functional antagonism)not yet gradedNo reviewed efficacy summary in this indication
DT-101Phase 2Small moleculeAMPA receptor (positive allosteric modulator)not yet gradedNo reviewed efficacy summary in this indication
ElunetiromPhase 2Small moleculeThyroid hormone receptor-betanot yet gradedNo reviewed efficacy summary in this indication
Emestedastat (Xanamem)Phase 2Small molecule11-beta-HSD1Partial signal
NCT05657691: Primary endpoint (Attention Composite cognitive score, week 6) missed: least squares mean change 0.32 (emestedastat) vs 0.46 (placebo), difference -0.13 (95% CI -0.32 to 0.06), p=0.17 favouring placebo. (MADRS depression score was only a secondary endpoint, borderline at p=0.05.) missed
Esketamine (CLE-100)Phase 2Small moleculeNMDA receptorPartial signal
NCT06340958: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score (29 days): CLE-100 -11.66 units on a scale (Standard Error 1.5) vs Placebo -8.7 units on a scale (Standard Error 1.55) missed
NCT04103892: Part B - Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score (29 days): Part B - CLE-100 (Oral Esketamine) -10.72 units on a scale (Standard Error 1.13) vs Part B - Placebo -9.46 units on a scale (Standard Error 1.31) missed
EvifacotrepPhase 2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
ForvisirvatPhase 2Small moleculeSIRT6Partial signal
NCT04479852: Change From Baseline to Week 4 in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Baseline to Week 4): SP-624 -12.6 Score on a scale (Standard Error 0.83) vs Placebo -10.8 Score on a scale (Standard Error 0.84) missed
GlyphAllo (allopregnanolone Prodrug) (SPT-300)Phase 2Small moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
GW117Phase 2Small moleculeMelatonin MT1/MT2 receptor + 5-HT2C receptorPartial signal
NCT06796868: Change in HAMD-17 total score from baseline at Week 8 (FAS, n=276): placebo -13.46, GW117 20mg -14.62, 40mg -14.34, 60mg -13.75; numerically greater reductions with GW117 but not statistically significant vs placebo. missed
HS-10353Phase 2Small moleculeGABA-A receptorWeak signal
NCT05195203: Phase 1 SAD (healthy, 2-55mg)/MAD (MDD patients, 15-65mg/day) trial: safe and well tolerated, no dose-adjusting AEs; exploratory HAM-D17 signal at 50mg dose: -4.7 vs placebo (95% CI -8.9 to -0.5), not significant at other doses
Hypidone (YL-0919)Phase 2Small moleculeSerotonin transporter/5-HT1A receptor/sigma-1 receptorPartial signalNo reviewed efficacy summary in this indication
IcalcaprantPhase 2Small moleculeKappa-opioid receptor (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
JNJ-89495120Phase 2Small moleculeMuscarinic M1 receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication
LiafensinePhase 2Small moleculeSerotonin/norepinephrine/dopamine transporterReliable signal
NCT05113771: Change in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score From Baseline to Day 42, in DGM4-positive Patients (Baseline to Day 42): Liafensine 1mg -15.4 Units on a Scale (Standard Error 1.25) | Liafensine 2mg -15.5 Units on a Scale (Standard Error 1.3) vs Placebo -11 Units on a Scale (Standard Error 1.31)
NCT01369095: In the CN162-007 study, the adjusted mean (SE) change in MADRS total score was -7.3 (0.830) and -6.6 (0.842) for BMS-820836 of 1 and 2 mg, respectively, and -6.9 (0.602) for the continuation group (P = 0.910). missed
LV232Phase 2Small moleculeSerotonin transporter + 5-HT3 receptorWeak signalNo reviewed efficacy summary in this indication
Mebufotenin (5-MeO-DMT) (GH001)Phase 2Small molecule5-HT2A receptorPartial signal
NCT05800860: Placebo-adjusted MADRS reduction from baseline at Day 8: -15.5 points (LS mean difference -15.5, effect size -2.0, P<0.0001)
NelivaptanPhase 2Small moleculeVasopressin V1B receptorPartial signal
NCT00358631: Change from baseline to Day 56 in HAM-D-17 total score (LS mean, SE): nelivaptan 250mg BID -10.7 (0.94) vs placebo -7.68 (0.95); difference from placebo -3.03 (95% CI -5.66 to -0.39; p=0.0244). 100mg BID nelivaptan and escitalopram 10mg QD arms did not separate from placebo.
NH102Phase 2Small moleculeSerotonin/norepinephrine/dopamine transporter + 5-HT2A receptorPartial signalNo reviewed efficacy summary in this indication
PDC-1421Phase 2BotanicalPolygalae radix extract (active components: tenuifolin, polygalasaponins, etc.)Partial signal
NCT02395978: Change of Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Week 6 Compared to Placebo for Part II. (From Baseline to Week 6): Part II: 2 PDC-1421 Capsule — ITT population: -13.19 score on a scale (Standard Deviation 9.68); PP population: -13.4 score on a scale (Standard Deviation 9.7) | Part II: 1 PDC-1421 Capsule Plus 1 Placebo — ITT population: -9.21 score on a scale (Standard Deviation 8.32); PP population: -10.4 score on a scale (Standard Deviation 5.18) vs Part II: 2 Placebo — ITT population: -9.2 score on a scale (Standard Deviation 7.98); PP population: -8.6 score on a scale (Standard Deviation 7.61)
Pramipexole / Ondansetron (ALTO-207)Phase 2Small moleculeDopamine D3-preferring D3/D2 receptors (agonist) + 5-HT3 receptornot yet gradedNo reviewed efficacy summary in this indication
RopanicantPhase 2Small moleculeAlpha4beta2 nicotinic acetylcholine receptorPartial signal
NCT06836063: MADRS total score change from baseline vs placebo at Week 6: mean difference -3.572 (FAS, p=0.038), -4.067 (PP set, p=0.023) -- primary endpoint met.
NCT03155503: Safe and well tolerated in healthy subjects at single doses up to 60 mg and multiple doses up to 45 mg once daily. Pharmacokinetics were nonlinear with accumulation on multiple dosing: 1.5- to 2.5-fold higher maximum concentration and 1.6- to 4.0-fold higher AUC from 0 to 24 h on day 14 compared with day 1.
SPN-820Phase 2Small moleculemTORC1Partial signal
NCT05066672: Change From Baseline to Week 4 in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score. (Baseline to Week 4): NV-5138 (800 or 1600 mg) -12.2 units on a scale (Standard Deviation 9.66) | Placebo -11.6 units on a scale (Standard Deviation 10.64) missed
SPN-821Phase 2Small moleculemTORC1 (mammalian target of rapamycin complex 1) (activator)not yet gradedNo reviewed efficacy summary in this indication
VLS-01Phase 2Small molecule5-HT2A receptornot yet gradedNo reviewed efficacy summary in this indication
ZelquistinelPhase 2Small moleculeNMDA receptorPartial signal
NCT03726658: Part A: Change in MADRS Score at 1 Day the Initial Dose of AGN-241751 Reported as Change From Baseline in Treated Group Compared With Change From Baseline in Placebo Group (Baseline (Day1) to Day 2): AGN-241751 3mg Daily -9.4 score on a scale (Standard Error 1.57) | AGN-241751 10mg Daily -6.7 score on a scale (Standard Error 1.58) | AGN-241751 25mg Daily -9.5 score on a scale (Standard Error 1.57) vs Placebo Daily -9.3 score on a scale (Standard Error 1.61) missed
ELE-101Phase 1/2Small molecule5-HT2A receptornot yet gradedNo reviewed efficacy summary in this indication
ApimostinelPhase 1Small moleculeNMDAR agonist/modulatorWeak signalFeatured results are safety only in this race
ENX-104Phase 1Small moleculeDopamine D2/D3 receptor (antagonist)Weak signalNo reviewed efficacy summary in this indication
LY03021Phase 1Small moleculeNorepinephrine/dopamine transporter + GABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
SEP-380135Phase 1Small molecule—Weak signalNo reviewed efficacy summary in this indication
SP-101Phase 1Small moleculeNMDA receptornot yet gradedNo reviewed efficacy summary in this indication
Itruvone
—(overall)
Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify MyCite)DiscontinuedCombinationDopamine D2 and serotonin 5-HT1A receptors (partial agonist); serotonin 5-HT2A receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Olanzapine / Fluoxetine (Symbyax)DiscontinuedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist); serotonin transporter (reuptake inhibitor)Reliable signal
NCT00035321: Primary endpoint, mean change in MADRS total score at 8 weeks (LOCF): Study 1 olanzapine/fluoxetine -11.0 vs fluoxetine -9.4 vs olanzapine -10.5, no statistically significant difference; Study 2 -14.5 vs -8.6 (p < .001) and -7.0 (p < .001); pooled -12.7 vs -9.0 (p < .001) and -8.8 (p < .001) (Thase et al., J Clin Psychiatry 2007).
OnfasprodilDiscontinuedSmall moleculeNMDA receptorPartial signal
NCT05454410: Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score 24 Hours (Day 2) After Injection (Baseline and 24 hours after SC injection): MIJ821 10 mg -14.1 Scores on a Scale (Standard Error 1.95) | MIJ821 4 mg -11.4 Scores on a Scale (Standard Error 2.04) | MIJ821 1 mg -8.4 Scores on a Scale (Standard Error 2.02) vs Placebo -8.9 Scores on a Scale (Standard Error 1.82)
NCT03756129: Change From Baseline in the Total Score of the Montgomery Asberg Depression Rating Scale (MADRS) at 24 Hrs (Baseline, and at 24 hours): Pooled MIJ821 0.16 mg/kg -15.51 Scores on a Scale (Standard Error 1.9) | Pooled MIJ821 0.32 mg/kg -12.98 Scores on a Scale (Standard Error 1.9) vs Ketamine 0.5 mg/kg Weekly -12.94 Scores on a Scale (Standard Error 2.7) | Placebo Weekly -7.27 Scores on a Scale (Standard Error 1.9)

Upcoming events

No upcoming readouts on record for this asset.